During a recent press conference, Swiss chocolatier Lindt & Sprüngli had a message for those who believe GLP-1 medications dampen demand for chocolate delicacies: the data suggests otherwise.
The premium chocolate maker reported double-digit organic growth in 2025, with sales climbing 12.4 percent to CHF 5.92 billion and operating profit reaching CHF 971 million. The results highlight the strength of the luxury chocolate category, even as the global confectionery industry grapples with record cocoa prices and economic uncertainty.
Part of that growth came from price adjustments across the company’s portfolio. Lindt implemented average price increases of roughly 19 percent in 2025 to offset soaring cocoa costs, yet demand remained strong.
But the company also pointed to an unexpected driver of premium chocolate demand: consumers using GLP-1 weight-loss medications. Data cited by the brand found that while about 15 percent of U.S. households use GLP-1 drugs, they account for roughly 17.5 percent of chocolate sales, suggesting consumers are still indulging, just in different ways.
According to Chief Executive Adalbert Lechner, many of those shoppers are simply shifting their habits, rather than eliminating treats entirely. As people cut back on calorie-dense foods like pizza, pasta and chips, they’re still seeking moments of indulgence—often choosing smaller portions of higher-quality products instead. He described it as a “less is more” mindset, where consumers opt for “small rewards with moments of bliss rather than mindless munching.”
That shift toward mindful indulgence is helping sustain demand for premium sweets even as wellness trends reshape the broader food landscape. In other words, consumers may be eating less, but when they do treat themselves, they’re reaching for better chocolate.
